Activated recombinant factor VIIa should not be used in patients with refractory variceal bleeding: It is mostly ineffective, is expensive, and may rarely cause serious adverse events

Margaret S. Sozio, Naga Chalasani

Research output: Contribution to journalArticle

3 Scopus citations
Original languageEnglish (US)
Pages (from-to)1786-1788
Number of pages3
Issue number5
StatePublished - Nov 1 2014

ASJC Scopus subject areas

  • Hepatology

Cite this